# A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

> **NCT06693843** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics** · enrollment: 220 (estimated)

## Conditions studied

- Obesity, Overweight, or Chronic Weight Management

## Interventions

- **DRUG:** Aleniglipron or Placebo
- **DRUG:** Aleniglipron or Placebo
- **DRUG:** Aleniglipron or Placebo
- **DRUG:** Aleniglipron
- **DRUG:** Aleniglipron
- **DRUG:** Aleniglipron
- **DRUG:** Aleniglipron

## Key facts

- **NCT ID:** NCT06693843
- **Lead sponsor:** Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-28
- **Primary completion:** 2025-10-24
- **Final completion:** 2026-08
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693843, "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06693843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*